https://pharmadog.xyz/news/592223 pharmadog en 2026-10-25T16:58:45.000Z AstraZeneca highlights broad oncology portfolio at ESMO conference https://pharmadog.xyz/news/592012 pharmadog en 2026-10-25T15:30:51.000Z Roche's KRAS G12C inhibitor cuts death risk by 44% versus Amgen and BMS in lung cancer trial https://pharmadog.xyz/news/592013 pharmadog en 2026-10-25T15:30:09.000Z AstraZeneca reports Tagrisso-Orpathys combo could prolong treatment for EGFR-mutant lung cancer https://pharmadog.xyz/news/591083 pharmadog en 2026-10-25T10:00:51.000Z Pfizer shifts focus after lung cancer trial setback, cites early signals in earlier-line patients; BioNTech and BMS report initial activity https://pharmadog.xyz/news/592156 pharmadog en 2026-10-25T09:47:00.000Z J&J touts promising RIPTAC data with 59% PSA reductions in prostate cancer trial https://pharmadog.xyz/news/590683 pharmadog en 2026-10-25T08:31:01.000Z Merck and Moderna’s mRNA melanoma vaccine cuts recurrence risk by 42% in Phase 3 trial https://pharmadog.xyz/news/588254 pharmadog en 2026-10-24T18:23:00.000Z Tonight We Ride recalls Ultimate Forza male supplement after finding undeclared sildenafil, tadalafil and dapoxetine https://pharmadog.xyz/news/587731 pharmadog en 2026-10-24T17:00:59.000Z Amgen and AstraZeneca present new combo data for extensive-stage small cell lung cancer at ESMO https://pharmadog.xyz/news/587411 pharmadog en 2026-10-24T16:00:12.000Z AstraZeneca, Lilly and Bayer unveil new strategies at ESMO 2026 in Madrid https://pharmadog.xyz/news/587075 pharmadog en 2026-10-24T14:30:56.000Z Amgen's Imdelltra plus AstraZeneca's Imfinzi cuts death risk by 58% in small cell lung cancer Phase 3 trial https://pharmadog.xyz/news/586340 pharmadog en 2026-10-24T11:00:00.000Z Opinion reflects on Theranos failures and the impracticality of its testing model https://pharmadog.xyz/news/586339 pharmadog en 2026-10-24T11:00:00.000Z Christina Applegate’s misdiagnosis highlights ongoing challenges in multiple sclerosis diagnosis https://pharmadog.xyz/news/586295 pharmadog en 2026-10-24T10:00:25.000Z Merck and Moderna present Phase 3 cancer vaccine data at ESMO26 amid Treasury proposal on China investment https://pharmadog.xyz/news/591987 pharmadog en 2026-10-24T09:45:00.000Z Roche reports superior survival for KRAS G12C inhibitor divarasib in phase 3 trial https://pharmadog.xyz/news/591986 pharmadog en 2026-10-24T09:07:00.000Z AstraZeneca says phase 3 ADC shows strong overall survival despite missing progression-free survival endpoint https://pharmadog.xyz/news/586438 pharmadog en 2026-10-24T06:25:00.000Z Merck and Moderna disclose phase 3 cancer vaccine data early after leak, showing improved recurrence-free survival with Keytruda https://pharmadog.xyz/news/584123 pharmadog en 2026-10-23T23:15:09.000Z Swiss biotech Windward Bio files for Nasdaq IPO to raise funds for China-derived assets and R&D https://pharmadog.xyz/news/583388 pharmadog en 2026-10-23T19:16:37.000Z ADA admits unclear policies after ejecting members, sparks boycott and journal shutdown https://pharmadog.xyz/news/583111 pharmadog en 2026-10-23T18:55:12.000Z Patient dies in Bristol Myers Squibb autoimmune CAR-T trial, raising safety concerns https://pharmadog.xyz/news/583112 pharmadog en 2026-10-23T18:48:10.000Z Few European-approved cancer drugs deliver high clinical benefit, analysis shows https://pharmadog.xyz/news/583067 pharmadog en 2026-10-23T18:36:40.000Z Bristol Myers Squibb identifies cause of safety signal in lupus CAR‑T trial